Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|November 25, 2017
A Controlled Trial of Erenumab for Episodic MigrainePeter J Goadsby, Uwe Reuter, Yngve Hallström, et al.
Cephalalgia : an International Journal of Headache|July 10, 2018
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled studyMessoud Ashina, Stewart Tepper, Jan Lewis Brandes, et al.
Cephalalgia : an International Journal of Headache|August 9, 2018
Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumabDawn C Buse, Richard B Lipton, Yngve Hallström, et al.
Cephalalgia : an International Journal of Headache|August 19, 2021
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studiesRichard B Lipton, David W Dodick, David Kudrow, et al.
Cephalalgia : an International Journal of Headache|February 24, 2018
ARISE: A Phase 3 randomized trial of erenumab for episodic migraineDavid W Dodick, Messoud Ashina, Jan Lewis Brandes, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
The Lancet. Neurology|March 12, 2014
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trialLudwig Kappos, Hans-Peter Hartung, Mark S Freedman, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind studyRichard B Lipton, Stewart J Tepper, Uwe Reuter, et al.
Headache|June 14, 2023
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysisStewart J Tepper, Richard B Lipton, Stephen D Silberstein, et al.
Pageof 6